drugset / Trial / NCT01624636
Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of successive intravenous (IV) doses of LFG316 in eligible patients with neovascular age-related macular degeneration (AMD)
Timeline
- Start
- 2012-12
- Primary completion
- 2013-05
- Completion
- 2013-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | tesidolumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | tesidolumab | Monoclonal antibody | 20 mg/kg | Intravenous |